FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.